The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
-
University of Alabama at Birmingham, Birmingham, Alabama, United States, 35294
Barrow Neurological Institute, Phoenix, Arizona, United States, 85013
Mayo Foundation for Medical Education and Research, Scottsdale, Arizona, United States, 85259
Banner Research Institute, Sun City, Arizona, United States, 85351
University of California San Diego, La Jolla, California, United States, 92093-0948
Keck School of Medicine of USC, Los Angeles, California, United States, 90033
University of California, San Francisco, San Francisco, California, United States, 94115
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States, 80045
Institute For Neurodegenerative Disorders, New Haven, Connecticut, United States, 06510
Parkinson's Disease& Movement Disorder Center of Boca Raton, Boca Raton, Florida, United States, 33486
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
30 Years to
ALL
Yes
Michael J. Fox Foundation for Parkinson's Research,
Kenneth L Marek, MD, PRINCIPAL_INVESTIGATOR, Institute for Neurodegenerative Disorders
Caroline Tanner, MD, PhD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco
2033-12